Episode 4: Adverse-Risk Acute Myeloid Leukemia Episode 4: Adverse-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Alexander Perl discuss adverse-risk acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Similar Survival, Less Toxicity With Decitabine vs Chemo in AML Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
For patients with acute myeloid leukemia, treatment with decitabine prior to stem cell transplantation had similar overall survival and much less toxicity compared with intensive chemotherapy.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 12, 2022 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Investor Update - June 10, 2022 Category: Pharmaceuticals Source Type: news

Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Media News - June 10, 2022 Category: Pharmaceuticals Source Type: news

Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 25, 2022 Category: Drugs & Pharmacology Source Type: news

Episode 3: Intermediate-Risk Acute Myeloid Leukemia Episode 3: Intermediate-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Pinkal Desai discuss intermediate-risk acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Spring House, Pa., May 5, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 between Janssen Research & Development, LLC, Genentech (a member of the Roche Group), Novartis, and Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, and recently expanded with additional members Amgen, AbbVie, and Kronos Bio, is advancing efforts to establish measurable residual disease (MRD) as a surrogate endpoint for overall ...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2022 Category: Hematology Source Type: news

Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML
THURSDAY, April 21, 2022 -- Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 21, 2022 Category: Pharmaceuticals Source Type: news

Episode 2: Good-Risk Acute Myeloid Leukemia Episode 2: Good-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Gautam Borthakur discuss good-risk acute myeloid leukemia.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2022 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news

Episode 1: Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia Episode 1: Acute Promyelocytic Leukemia: A Subset of Acute Myeloid Leukemia
Drs Gail Roboz and Farhad Ravandi discuss acute promyelocytic leukemia, a relatively uncommon subset of acute myeloid leukemia.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 14, 2022 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news

Africa: First Case of HIV Cure in a Woman After Stem Cell Transplantation Reported At CROI-2022
[WHO] The International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1107 reported the first case of HIV cure in a woman living with HIV submitted to a dual stem cell transplant (i.e., an umbilical cord blood transplant combined with a half-matched bone marrow transplant) for treatment of an acute myelogenous leukemia. The IMPAACT P1107 researchers presented the case details during the oral abstract session held at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 202 (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - April 4, 2022 Category: Infectious Diseases Source Type: news

Survival Inferior in Black Patients With Acute Myeloid Leukemia
Most disparities in acute myeloid leukemia mortality death accounted for by census tract measures (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 23, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Survival Inferior in Black Patients With Acute Myeloid Leukemia
WEDNESDAY, March 23, 2022 -- For patients with acute myeloid leukemia (AML), non-Hispanic Black individuals have inferior survival to non-Hispanic White individuals, with census tract measures accounting for most of the disparities in survival,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2022 Category: Pharmaceuticals Source Type: news

TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Allogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland, March 17, 2022 -- (Healthcare Sales & Marketing Network) -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "... Biopharmaceuticals, Oncology, FDA TC Biopharm, T cell therapy, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2022 Category: Pharmaceuticals Source Type: news